Telix Pharmaceuticals Limited Company Information
Telix Pharmaceuticals Limited's employee growth, exchange listings and data sources
Key Information
- Name: Telix Pharmaceuticals Limited
- Ticker: TLX
- Exchange: ASX
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$8.351b
- Shares Outstanding: 334.72m
- Website: https://telixpharma.com
Number of Employees
Location
- Telix Pharmaceuticals Limited
- 55 Flemington Road
- Suite 401
- North Melbourne
- Victoria
- 3051
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TLX | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Nov 2017 |
| TLX | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Nov 2017 |
| TLPP.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Nov 2017 |
| T3X | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Nov 2017 |
| TLX | NasdaqGS (Nasdaq Global Select) | SPON ADS EACH REP 1 ORD SHS | US | USD | Nov 2024 | |
| T3X0 | DB (Deutsche Boerse AG) | SPON ADS EACH REP 1 ORD SHS | DE | EUR | Nov 2024 |
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 03:19 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 03:19 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Telix Pharmaceuticals Limited is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | Barclay Pearce Capital Pty Limited |
| John Hester | Bell Potter |
| Andrew Paine | CLSA |